Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial

Chen, Jianhua; Liu, Bingyang; Zhang, Fang; Cui, Weiping; Zhang, Peng

doi:10.1007/s00280-019-03828-z

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lobaplatin (LBP) is a third-generation platinum antitumor drug, which is clinically used for the treatment of chronic metastatic breast cancer, myelogenous leukemia, and small cell lung cancer in China . It has been reported that lobaplatin suppressed cancer metastasis and developed antitumor activity by arresting cell cycle progression to inhibit cancer cell proliferation and induce cancer cell apoptosis. − LBP is usually administered intravenously because of its good solubility, but the rapid hydrolysis of the drug in vivo would generate varying degrees of side effects, such as gastrointestinal toxicity, nephrotoxicity, myelosuppression, and thrombocytopenia, which largely restrict the clinical applications. − It will be seen that improving the stability of platinum-based anticancer agents in the gastrointestinal fluid is the primary issue for making them into an oral formulation, and it is expected to reduce toxicity . Therefore, it is worthwhile to further develop a new form of platinum-based anticancer agent with high stability in gastrointestinal fluid, high efficiency, and reduced toxicity.…”

Section: Introductionmentioning

confidence: 99%

Strategy to Tune the Performance of Two Drug Components: Drug–Drug Cocrystals of Lobaplatin with Flavonoids

Yin

Xie

Jiang

et al. 2022

Crystal Growth & Design

View full text Add to dashboard Cite

A cocrystallization technique was utilized to improve the performance of lobaplatin, and five cocrystals of lobaplatin with a variety of flavonoids, including quercetin, myricetin, fisetin, naringenin, and luteolin, were successfully obtained. The solubility, dissolution, and stability of the cocrystals were further evaluated, the results presented that the cocrystals have reduced solubilities, slowrelease rates, and delayed hydrolysis performances compared to lobaplatin. Meanwhile, the solubilities and dissolution rates of the flavonoids were dramatically improved. In addition, CCK-8 assay was used to evaluate the antitumor activity of the cocrystals, which shows that the cocrystals of lobaplatin-luteolin monohydrate, lobaplatinmyricetin monohydrate, and lobaplatin-fisetin monohydrate exhibit superior performances to lobaplatin. These findings may provide a promising solution for overcoming some weaknesses of the parent drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Strategy to Tune the Performance of Two Drug Components: Drug–Drug Cocrystals of Lobaplatin with Flavonoids

Yin

Xie

Jiang

et al. 2022

Crystal Growth & Design

View full text Add to dashboard Cite

show abstract

“…Many clinical trials suggest the effectiveness of lobaplatin in treating various cancers, including breast cancer and small cell lung cancers. 11 , 12 In the present study, we retrospectively analyzed and compared the toxicity, efficacy and long-term survival of lobaplatin-based combined chemotherapy with cisplatin-based combined chemotherapy in cervical cancer patients from two medical institutions.…”

Section: Introductionmentioning

confidence: 99%

A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study

Tian¹,

Yang²,

Feng-hu³

et al. 2021

CMAR

View full text Add to dashboard Cite

Association between microRNA 21 expression in serum and lung cancer

Qiao¹,

Luo²,

Liu

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Previous studies have reported that microRNA 21 (mRNA 21) has involved in the procedure of lung cancer (LC). However, its conclusions are still unclear. Thus, this study will try to elaborate the association between mRNA 21 expression in serum and LC. Methods: The electronic databases of Cochrane Library, PubMed, EMBASE, Allied and Complementary Medicine Database, WANGFANG database, and China National Knowledge Infrastructure will be retrieved from the inception to the present. All electronic databases will be searched without limitations of language and geographical location. Case-controlled studies reporting the association between mRNA 21 expression in serum and LC will be included. In addition, we will also identify other literature sources to avoid missing potential studies. All study selection, information collection, and study quality assessment will be performed by 2 independent authors. RevMan V.5.3 software and Stata V.12.0 software will be used for data synthesis and analysis. Results: This study will summarize current evidence to investigate the association between mRNA 21 expression in serum and LC. Conclusion: The findings of this study will present comprehensive evidence to determine whether mRNA 21 expression in serum is relevant with LC or not. Systematic review registration: INPLASY202040055.

show abstract

Pharmacokinetics and safety of lobaplatin plus etoposide in Chinese men older than 65 years with extensive-stage small cell lung cancer: a phase II clinical trial

Cited by 3 publications

References 24 publications

Strategy to Tune the Performance of Two Drug Components: Drug–Drug Cocrystals of Lobaplatin with Flavonoids

Strategy to Tune the Performance of Two Drug Components: Drug–Drug Cocrystals of Lobaplatin with Flavonoids

A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study

Association between microRNA 21 expression in serum and lung cancer

Contact Info

Product

Resources

About